Rational Design of an Epidermal Growth Factor Receptor Vaccine: Immunogenicity and Antitumor Research DOI Creative Commons
Yifei Liu, Zehui Liu, Zhongliang Zheng

и другие.

Biomolecules, Год журнала: 2024, Номер 14(12), С. 1620 - 1620

Опубликована: Дек. 18, 2024

The epidermal growth factor receptor (EGFR) is frequently overexpressed in a variety of human epithelial tumors, and its aberrant activation plays pivotal role promoting tumor growth, invasion, metastasis. clinically approved passive EGFR-related therapies have numerous limitations. Seven EGFR-ECD epitope peptides (EG1-7) were selected through bioinformatics prediction tools including NetMHCpan-4.1, NetMHCIIpan-3.2, IEDB Consensus (v2.18 v2.22) fused to the translocation domain diphtheria toxin (DTT). A549 model was successfully established murine mouse model. vaccine formulated by combining adjuvants Alum CpG subsequently assessed for immunogenicity anti-tumor efficacy. DTT-EG (3;5;6;7) vaccines elicited specific humoral cellular immune responses effectively suppressed both prophylactic therapeutic models. epitopes EG3 (HGAVRFSNNPALCNV145-159), EG5 (KDSLSINATNIKHFK346-360), EG6 (VKEITGFLLIQAWPE398-412), EG7 (LCYANTINWKKLFGT469-483) incorporated into active immunization, representing promising strategy treatment tumors with (EGFR). design fusion method employed this study demonstrate viable approach toward development cancer vaccines.

Язык: Английский

Immunogenicity and Safety Profile of Two Adjuvanted-PD-L1-Based Vaccine Candidates in Mice, Rats, Rabbits, and Cynomolgus Monkeys DOI Creative Commons
Camila Canaan-Haden-Ayala,

J. Sánchez-Ramírez,

Rafael Martínez-Castillo

и другие.

Vaccines, Год журнала: 2025, Номер 13(3), С. 296 - 296

Опубликована: Март 11, 2025

Background: The therapeutic blockade of the PD1/PD-L1 axis with monoclonal antibodies has led to a breakthrough in cancer treatment, as it plays key role immune evasion tumors. Nevertheless, treating patients vaccines that stimulate targeted response is another attractive approach for which few side effects have been observed combination immunotherapy clinical trials. In this sense, our group recently developed vaccine candidate called PKPD-L1Vac contains an antigen extracellular domain human PD-L1 fused 47 amino-terminal, part LpdA gene N. meningitides, produced E. coli. investigation potential toxicities associated by new therapy preclinical studies critical optimizing efficacy and safety therapy. Methods: Here, we describe immunogenicity preliminary mice, rats, rabbits, non-human primates make use 200 μg dose PKPD-L1 VSSPs or alum phosphate contribute assessment adverse events are relevant future development program novel candidate. Results: administration four species at doses studied was immunogenic did not result behavioral, clinical, hematological, serum biochemical changes. Conclusions: Therefore, could be considered suitable further complex toxicological way its evaluation humans opened.

Язык: Английский

Процитировано

0
Cancer-associated fibroblasts derived amphiregulin promotes HNSCC progression and drug resistance of EGFR inhibitor DOI

Jinhan Zhou,

Yi Xu, Yining Li

и другие.

Cancer Letters, Год журнала: 2025, Номер unknown, С. 217710 - 217710

Опубликована: Апрель 1, 2025

Язык: Английский

Процитировано

0
The progress of tumor vaccines clinical trials in non-small cell lung cancer DOI Creative Commons
Xiaomu Wang,

Yunping Niu,

芳久 渡辺

и другие.

Clinical & Translational Oncology, Год журнала: 2024, Номер 27(3), С. 1062 - 1074

Опубликована: Авг. 23, 2024

Non-small cell lung cancer (NSCLC) remains a significant global health challenge, with high mortality rates and limited treatment options. Tumor vaccines have emerged as potential therapeutic approach, aiming to stimulate the immune system specifically target tumor cells. This study screened 283 clinical trials registered on ClinicalTrials.gov through July 31, 2023. After excluding data that did not meet inclusion criteria, total of 108 were assessed. Data number, title, status, vaccine types, results, conditions, interventions, outcome measures, sponsor, collaborators, drug target, phases, enrollment, start date, completion date locations extracted analyzed. The number for NSCLC has continued increase in recent years, majority which conducted United States. Most at stages ranging from Phase I II. Peptide-based accounted largest proportion. Others include vaccines, DNA/RNA viral vector DC vaccines. Several promising candidates shown encouraging results early-phase trials. However, challenges such heterogeneity antigens escape mechanisms still need be addressed. represent avenue NSCLC. Ongoing are crucial optimizing strategies identifying most effective combinations. Further research is needed overcome existing limitations translate these findings into practice, offering new hope patients.

Язык: Английский

Процитировано

4
TARGET ONCOGENIC RECEPTORS IN TUMOURS, FROM ITS INITIAL CLINICAL BREAKTHROUGHS TO CURRENT CLINICAL STANDARD THERAPY DOI Open Access

George Zhu

Universal Journal of Pharmaceutical Research, Год журнала: 2024, Номер unknown

Опубликована: Март 15, 2024

Epidermal growth factor (EGF) is a polypeptide hormone originally isolated from mouse submaxillary gland, which potent mitogen for wide variety of culture cells both epithelial and mesenchymal origin, its important role in the proliferation, differentiation, survival neural glial precursor cells. The physiological effects EGF are mediated by an receptor with tyrosine-specific protein kinase activity. traditionally accepted view that normal epidermal (EGFR) no tumorigenic, whereas mutated EGFR such as oncogenic EGFRvIII oncogenic. In recent, it has been implicated could be beneficial burn, wound healing, diabetic foot ulcer, show attractive perspective. addition, cosmetic containing would effective improving plasticity skin, helps anti-aging whitening, controls amount erythema sebum skin. our team we have successfully prepared series 350 bottles Shampoo liquid 26 recombinant human (rhEGF) spray, 4 EGF-Silvadence ointment. initial results indicated rhEGF safe available clinical use. On other hand, progress on interaction altered signaling through downstream molecules Ras/Raf/MAPK (see figure full text, George Zhu,1991) and/or PI3k/akt pathway development some cancers A431 epidermoid carcinoma cells, brain glioblastoma, breast, pancreas lung cancers. addition to gefitinib, erlotinib, osimertinib CIMA vax-EGF vaccine, antioncogenic antibody based fusion [for example Cetuximab-based IL-10 protein, CmAb-(IL10)2] provide potential strategy improve cancer immunotherapy. Peer Review History: Received 1 December 2023; Revised January 2024; Accepted 2 March; Available online 15 March 2024 Academic Editor: Dr. Tamer Elhabibi, Suez Canal University, Egypt, [email protected] Average review marks at stage: 6.0/10 publication 8.0/10 Reviewers: Bilge Ahsen KARA, Ankara Gazi Mustafa Kemal Hospital, Turkey, [email protected] Asia Selman Abdullah, University Basrah, Iraq, [email protected]

Язык: Английский

Процитировано

1
Peptide Vaccines in Cancer Immunotherapy DOI Creative Commons
Yunqing Jiang

MedScien, Год журнала: 2024, Номер 1(7)

Опубликована: Июнь 6, 2024

Traditional cancer treatment is based on surgery, supplemented by chemotherapy and radiotherapy. In recent years, new options, such as targeted therapy, have gradually entered the clinic. However, for some patients who are inoperable or metastasized, there currently no sufficiently effective therapies to support long-term survival. Peptide vaccines autoimmune system-based that typically target uptake of tumor antigens antigen-presenting cells (APCs). Current clinical trials peptide primarily tumor-associated tumor-specific (TAAs TSAs) can be classified into two types: synthetic derived from whole cells. Although been reported promising, microenvironment (TME) a significant obstacle effectiveness immunotherapy. Using future tumors, surgical follow-up, complement other treatments immune checkpoint inhibitors, tyrosine kinase chemotherapy, radiotherapy possibility. This study aims examine various types applications peptide-based therapeutic vaccines, which may offer insights current development these vaccines.

Язык: Английский

Процитировано

1
Novel vaccines against lung cancer DOI

Sofia Baka,

George Iraklis,

Evanthia Papadopoulou

и другие.

Current Opinion in Oncology, Год журнала: 2024, Номер unknown

Опубликована: Окт. 1, 2024

Purpose of review Despite recent advances in immunotherapy treatment for metastatic, early-stage nonsmall cell lung cancer (NSCLC), palliative, adjuvant, neoadjuvant, and perioperative options, further development is needed. Exploring new frontiers immuno-oncology necessary. Researchers are interested a therapeutic vaccination model. Recent findings In this paper, we provide the latest vaccines. We describe strategies antigen selection delivery platforms. As 5 th August 2024, have reviewed ongoing clinical trials results. summarize most important novel vaccines, way action, available data. also discuss pros cons various types Summary Until recently, trial results were mixed regarding efficacy vaccines cancer. Developing next-generation sequencing bioinformatic technologies has helped identify suitable antigens. New personalized based on neoantigens specific to unique tumor mutations. Neoantigens, instead tumor-associated antigens, better systems adjuvants will improve presentation immune system activation. Combining these with other approaches prolong response.

Язык: Английский

Процитировано

1
Identification and evaluation of tumor pyroptosis-associated antigens for design a vaccine candidate against lung cancer DOI Creative Commons
Truc Ly Nguyen, Heebal Kim

Research Square (Research Square), Год журнала: 2024, Номер unknown

Опубликована: Ноя. 5, 2024

Abstract Lung cancer is the leading cause of cancer-related mortality worldwide, necessitating development new treatment strategies. This study aims to design a novel multi-epitope vaccine targeting pyroptosis-associated proteins (CARD8, NAIP, NLRP1, and NLRP3) using immunoinformatics. T-cell B-cell epitopes were identified from these assessed for antigenicity, non-toxicity, immune-stimulatory potential. Fifteen with high scores selected combined suitable adjuvants linkers form construct. The three-dimensional structure was predicted, refined, validated through molecular modeling techniques. Molecular dynamics simulations confirmed vaccine's structural stability flexibility under physiological conditions. Furthermore, in silico immune suggested that could elicit strong humoral cellular responses, including antibody production robust T-helper T-cytotoxic cell activation. These findings suggest vaccine’s potential generate long-term immunity. While computational predictions are promising, vitro vivo validation required confirm efficacy safety. highlights pyroptosis pathways lung underscores value tools accelerating design. If proven effective experimental settings, this contribute more immunotherapies, offering avenue disease limited options.

Язык: Английский

Процитировано

0
Rational Design of an Epidermal Growth Factor Receptor Vaccine: Immunogenicity and Antitumor Research DOI Creative Commons
Yifei Liu, Zehui Liu, Zhongliang Zheng

и другие.

Biomolecules, Год журнала: 2024, Номер 14(12), С. 1620 - 1620

Опубликована: Дек. 18, 2024

The epidermal growth factor receptor (EGFR) is frequently overexpressed in a variety of human epithelial tumors, and its aberrant activation plays pivotal role promoting tumor growth, invasion, metastasis. clinically approved passive EGFR-related therapies have numerous limitations. Seven EGFR-ECD epitope peptides (EG1-7) were selected through bioinformatics prediction tools including NetMHCpan-4.1, NetMHCIIpan-3.2, IEDB Consensus (v2.18 v2.22) fused to the translocation domain diphtheria toxin (DTT). A549 model was successfully established murine mouse model. vaccine formulated by combining adjuvants Alum CpG subsequently assessed for immunogenicity anti-tumor efficacy. DTT-EG (3;5;6;7) vaccines elicited specific humoral cellular immune responses effectively suppressed both prophylactic therapeutic models. epitopes EG3 (HGAVRFSNNPALCNV145-159), EG5 (KDSLSINATNIKHFK346-360), EG6 (VKEITGFLLIQAWPE398-412), EG7 (LCYANTINWKKLFGT469-483) incorporated into active immunization, representing promising strategy treatment tumors with (EGFR). design fusion method employed this study demonstrate viable approach toward development cancer vaccines.

Язык: Английский

Процитировано

0